Imperial College London
Alternate

Dr. Channa Jayasena MA PhD MRCP FRCPath

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Reader in Reproductive Endocrinology
 
 
 
//

Contact

 

c.jayasena Website

 
 
//

Location

 

6N5CCommonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{de:2023:clinem/dgad610,
author = {de, Silva NL and Dissanayake, H and Kalra, S and Meeran, K and Somasundaram, NP and Jayasena, CN},
doi = {clinem/dgad610},
journal = {J Clin Endocrinol Metab},
title = {Global barriers to accessing off-patent endocrine therapies: a renaissance of the orphan disease?},
url = {http://dx.doi.org/10.1210/clinem/dgad610},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - CONTEXT: Clinical endocrinology encompasses many diseases requiring long-term drug therapy. Prohibitive pricing of some endocrine drugs classified as essential by the World Health Organisation has created sub-optimal care of patients with endocrine disorders. EVIDENCE ACQUISITION: This review is based on evidence obtained from several databases and search engines including PubMed, Google and Google Scholar, reference searches, manual searching for web pages of international regulatory bodies and the authors' experience from different healthcare settings. EVIDENCE SYNTHESIS: After the expiry of a patent, generic versions with the opportunity for increased availability and a price reduction are expected. There are access barriers worldwide for many off-patent endocrine drugs. The high price is the main issue for several medicines including insulin, hydrocortisone, testosterone, and gonadotropins. This is contributed to by several factors including the market monopoly due to the lack of registered generics or suppliers limiting the benefit of competition and a complex supply chain. Additionally, the lack of some medicines had been concerning due to market factors such as the relatively small number of patients making it less attractive for the manufacturers. Commissioning of non-profit manufacturers and state manufacturing as well as strict price control measures could alleviate this situation. CONCLUSIONS: Lack of availability and disproportionate price inflation affecting essential off-patent endocrine therapies is common due to several interrelated factors. Global collaboration among healthcare organisations with the support of policy-making bodies might be needed to mitigate this.
AU  - de,Silva NL
AU  - Dissanayake,H
AU  - Kalra,S
AU  - Meeran,K
AU  - Somasundaram,NP
AU  - Jayasena,CN
DO  - clinem/dgad610
PY  - 2023///
TI  - Global barriers to accessing off-patent endocrine therapies: a renaissance of the orphan disease?
T2  - J Clin Endocrinol Metab
UR  - http://dx.doi.org/10.1210/clinem/dgad610
UR  - https://www.ncbi.nlm.nih.gov/pubmed/37846800
ER  -
Download